Quarterly ResultAug 11, 2026, 08:22 AM
Theriva Biologics Q2 Net Loss $(3.2M); Going Concern Warning
AI Summary
Theriva Biologics reported a net loss of $(3.217) million for the second quarter of 2026, a substantial improvement from $(13.058) million in the same period last year, with net loss per share improving to $(0.07). Despite this, the company's financial statements include a going concern warning, indicating a dependency on securing additional financing or strategic partnerships to continue operations beyond the first quarter of 2027. The company generated $300 thousand in license revenue for the six months ended June 30, 2026, and expects $1.8 million in annual savings from a September 2025 workforce reduction.
Key Highlights
- Q2 2026 Net Loss was $(3.217) million, significantly reduced from $(13.058) million YoY.
- Q2 2026 Net Loss Per Share was $(0.07), improved from $(1.93) YoY.
- Cash and cash equivalents totaled $11.337 million as of June 30, 2026.
- Company faces substantial doubt about its ability to continue as a going concern.
- Current cash is expected to fund operations into the first quarter of 2027.
- License revenue of $300 thousand was recognized for the six months ended June 30, 2026.
- Workforce reduction in September 2025 is expected to save $1.8 million annually.
- Entered a license agreement with Rasayana Therapeutics for SYN-020 in February 2026.
Price Impact
More from TOVX